Prime Medicine (PRME) Income from Continuing Operations (2021 - 2026)

Prime Medicine has reported Income from Continuing Operations for 6 years, with the latest figure at 49633000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 4.35% year-over-year to 49633000.0; the trailing twelve-month figure through Mar 2026 stood at 202581000.0 (changed 0.28% YoY), and the FY2025 full-year result was 204201000.0, down 4.25% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 49633000.0, down from 47525000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 23840000.0 in Q1 2022, with the low at 65643000.0 in Q4 2023.
• Historically, Income from Continuing Operations has averaged 45312176.47 across 5 years, with a median of 47525000.0 in 2025.
• The largest YoY upside for Income from Continuing Operations was 37.54% in 2022 against a maximum downside of 78.83% in 2022.
• Prime Medicine's Income from Continuing Operations stood at 39283000.0 in 2022, then slumped by 67.1% to 65643000.0 in 2023, then soared by 35.6% to 42276000.0 in 2024, then slipped by 12.42% to 47525000.0 in 2025, then fell by 4.44% to 49633000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 49633000.0 (Q1 2026), 47525000.0 (Q4 2025), and 52832000.0 (Q3 2025), per Business Quant data.